CE
Therapeutic Areas
Mosaic ImmunoEngineering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Acquired Necroptosis Assets (from Oncotelic) | Cancer | Clinical |
Leadership Team at Mosaic ImmunoEngineering
SK
Steven King
President and Chief Executive Officer, Director
PL
Paul Lytle
EVP, Chief Financial Officer, Director
MG
Marvin Garovoy, MD
Head of Medical Immuno-Oncology
SF
Shelley Fussey, Ph.D.
VP, Intellectual Property
RG
Robert Garnick, Ph.D.
Director
RA
Robert A. Baffi, Ph.D.
Director